Physician profile
Inna Lazar
NPI 1255713079
$146,996.38
in general payments reported to CMS, 2019-2025
33 companies · $40K in 2025
The $40K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,680 · 2020: $452 · 2021: $3,361 · 2022: $24K · 2023: $17K · 2024: $61K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $60K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Travel and Lodging: $9,796 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $9,600 · Consulting Fee: $7,295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $59,995.51 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,205.00 |
| Travel and Lodging | $9,796.10 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $9,600.00 |
| Consulting Fee | $7,295.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis Be INC | $73,076.78 | 2022-2025 | M22, Optilight |
| Bausch & Lomb Americas INC. | $21,833.72 | 2022-2025 | Infuse, Miebo, Xiidra |
| Sun Pharmaceutical Industries INC. | $16,662.69 | 2021-2025 | Cequa |
| Alcon Vision LLC | $16,337.71 | 2019-2025 | Pataday, Eysuvis, Tryptyr |
| Coopervision INC. | $6,811.38 | 2020-2025 | Misight Contact Lens, Myday Contact Lens |
| Abbvie INC. | $3,175.63 | 2024-2025 | |
| Tarsus Pharmaceuticals, INC. | $1,732.02 | 2024-2025 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $1,706.18 | 2019-2023 | Acuvue |
| Allergan, INC. | $1,297.14 | 2020-2022 | |
| Kala Pharmaceuticals, INC. | $1,141.98 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $729.78 | 2019-2021 | |
| Biotissue Holdings INC. | $433.98 | 2021-2025 | |
| Dompe US, INC. | $384.04 | 2021-2025 | Oxervate |
| Oyster Point Pharma, INC. | $263.59 | 2022-2025 | Tyrvaya, Ryzumvi |
| Sight Sciences, INC. | $234.41 | 2019-2024 | Tearcare System |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abb Con-Cise Optical Group LLC | $230.39 | 2024-2025 | Contact Lens, Spectacle Lenses |
| Novartis Pharmaceuticals Corporation | $213.29 | 2020-2023 | |
| Shire North American Group INC | $190.96 | 2019 | |
| Eyevance Pharmaceuticals LLC | $154.06 | 2021 | |
| Amgen INC. | $109.00 | 2024-2025 | Tepezza |
| Harrow Eye, LLC | $70.01 | 2024 | Vevye, Natacyn |
| Carl Zeiss Meditec USA, INC. | $23.58 | 2022 | |
| Visioneering Technologies, INC. | $23.19 | 2020 | |
| Topcon Healthcare, INC. | $22.10 | 2022 | |
| Lkc Technologies, INC. | $20.47 | 2025 | |
| Oasis Medical, INC. | $18.64 | 2024 | Oasis Tears |
| Thea Pharma INC. | $17.55 | 2025 | Iyuzeh |
| Carl Zeiss Meditec Ag | $17.20 | 2020 | |
| Aerie Pharmaceuticals, INC. | $16.46 | 2021 | |
| Maculogix, INC. | $13.30 | 2021 | |
| Tearlab Corp | $12.85 | 2023 | Tearlab Osmolarity System |
| Johnson & Johnson Surgical Vision, INC. | $12.18 | 2019 | |
| Optos, INC. | $10.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inna Lazar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.